2001
Enrollment begins
The Registry starts collecting baseline and longitudinal information from people with confirmed Fabry disease.
2006–2008
Early cohort analyses
Published work describes baseline characteristics, pediatric disease, and major organ involvement in women.
2010s
Growing longitudinal evidence
Registry analyses expand into renal outcomes, cardiac events, cerebrovascular disease, survival, regional cohorts, and treatment outcomes.
2021
Two decades of participation
A Sanofi overview reports more than 7,000 participants across over 40 countries and more than 25 publications.
Today
Current study channels
The observational study remains listed by Sanofi and ClinicalTrials.gov under NCT00196742.
